Postmenopausal Endometriosis: Risks and Key Insights
Understanding persistence after menopause and the rare risk of malignant change.
Postmenopausal Malignant Transformation of Endometriosis
Endometriosis is a condition that causes pain and infertility and predominantly affects premenopausal women. Estimates suggest that up to 10% of women worldwide experience the condition during their reproductive years. Although postmenopausal endometriosis is much less common, studies indicate it may still occur in approximately 2.5% of women, dispelling the misconception that endometriosis is exclusively a disease of younger women.
Despite being a benign disorder, endometriosis carries a risk of malignant transformation at all ages. This discussion explores the potential for such transformation in the postmenopausal population.
Understanding Endometriosis and Menopause
Postmenopausal endometriosis refers to the occurrence or persistence of endometriosis symptoms after menopause, which typically occurs around age 50 and is defined by the cessation of menstrual cycles for twelve consecutive months. After menopause, ovarian estrogen production becomes minimal, and estrogen is generally considered essential for the growth of endometriotic tissue. As a result, many cases naturally diminish. However, for some postmenopausal women, endometriosis persists or even appears de novo.
The causes of endometriosis in younger women remain controversial and incompletely defined. Through uncertain but likely multifactorial mechanisms, endometriosis is characterized by ectopic endometrial-like tissue growing outside the uterus. While one might expect the hypoestrogenic state associated with menopause to lessen symptoms, this is not universally observed.
In postmenopausal women, several mechanisms may contribute to endometriosis. Residual disease that began before menopause can continue due to persistence of lesions that respond to factors other than estrogen or because of heightened sensitivity to even low estrogen levels. Exogenous estrogen from hormone replacement therapy (HRT) may stimulate endometrial cells; estrogen-only regimens, in particular, can reactivate implants or potentially initiate new growths. Endogenous estrogen production also plays a role because adipose tissue can convert other hormones into estrogen. Women with higher amounts of adipose tissue might generate enough estrogen to promote endometriosis, and fat can store xeno-estrogens from certain toxins and release them over time. Moreover, the tissue microenvironment around endometriotic lesions can support local estrogen production.
Malignant Transformation: A Rare but Possible Event
Endometriosis is overwhelmingly benign, yet research has shown an increased risk of certain ovarian cancers among women with endometriosis, especially clear cell and endometrioid ovarian carcinomas.
Multiple factors may influence the likelihood of malignant transformation. The duration of endometriosis matters because prolonged presence of lesions increases cumulative time in an inflammatory state, and chronic inflammation is a known contributor to cancer development. As age advances, overall cancer risk rises, so persistent endometriosis after menopause hypothetically compounds this risk. Exogenous estrogen exposure through HRT can stimulate lesion growth and may contribute to malignant change, although this has not been definitively proven and is complicated by individual differences in estrogen levels and receptor activity.
Genetic and epigenetic influences are also important. Certain mutations may predispose some women to both deeply invasive endometriosis and ovarian cancer, creating an area of overlap between the two conditions. Epigenetic regulation, which governs gene activation and is shaped by environmental exposures, likely contributes over time, with a potential cumulative effect of active mutations across the years. Among the notable genetic factors, PTEN functions as a tumor suppressor and is found mutated in both endometriosis and in endometrioid and clear cell ovarian cancers; loss of PTEN function can drive uncontrolled cell growth and may facilitate malignant transformation. ARID1A mutations, commonly identified in endometriosis-associated ovarian cancers, disrupt chromatin remodeling and DNA repair, thereby promoting oncogenesis. KRAS and BRAF mutations, implicated in the pathogenesis of multiple cancers, have been detected in benign endometriotic lesions and may participate in early steps toward malignancy. Inherited mutations in BRCA1 and BRCA2, well known for their association with breast and ovarian cancers, may also increase the risk of developing endometriosis and its potential progression to malignancy.
Conclusions
Although less common than in premenopausal women, postmenopausal endometriosis remains clinically meaningful. The absolute risk of malignant transformation is very low, yet it underscores the value of regular monitoring and consultations with endometriosis specialists for postmenopausal women who have endometriosis or symptoms suggestive of it. When postmenopausal endometriosis is suspected or diagnosed—particularly if it appears invasive or is accompanied by unusual symptoms or pelvic masses—seeking evaluation from a gynecologic oncologist is a prudent step.
References
Bulun SE. Endometriosis. N Engl J Med. 2009;360(3):268–279.
Pearce CL, Templeman C, Rossing MA, et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol. 2012;13(4):385–394.
Giannella L, Marconi C, Di Giuseppe J, et al. Malignant Transformation of Postmenopausal Endometriosis: A Systematic Review of the Literature. Cancers (Basel). 2021 Aug 10;13(16):4026.
Giannella L, Marconi C, Di Giuseppe J, et al. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. Gynecol Oncol. 2011;123(1):157–163.
Sato N, Tsunoda H, Nishida M, et al. Loss of heterozygosity on 10q23.3 and mutation of the tumor suppressor gene PTEN in benign endometrial cyst of the ovary: possible sequence progression from benign endometrial cyst to endometrioid carcinoma and clear cell carcinoma of the ovary. Cancer Res. 2000;60(24):7052–7056.
Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med. 2010;363(16):1532–1543.
Dinulescu DM, Ince TA, Quade BJ, Shafer SA, Crowley D, Jacks T. Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med. 2005;11(1):63–70.
Saha R, Pettersson H, Svedberg P, et al. Endometriosis and the risk of ovarian and endometrial adenocarcinomas: a meta-analysis. BMJ Open. 2020;10(4):e034760.